Startup profile · funding coverage
Vedana Therapeutics funding, valuation and investors
Biotech developing next-gen PACAP-targeting migraine prevention antibodies.
Keep track of Vedana Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$46M · June 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$46M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Seattle, WA
Investors in latest funding
Lead: Canaan Partners
Overview
Vedana Therapeutics emerged from stealth in June 2026 with $46M Series A co-led by Westlake BioPartners and Canaan Partners to advance antibody therapies for migraine prevention targeting PACAP biology and combination CGRP/PACAP approaches. Leadership includes executives who developed approved CGRP migraine antibodies. Based in Seattle, proceeds advance subcutaneous antibody programs toward human trials.
Why Vedana Therapeutics is interesting
Migraine has CGRP winners — Vedana bets PACAP and dual-pathway antibodies are the next clinical frontier from the team that already shipped migraine blockbusters.
Product & use cases
Subcutaneously delivered antibody portfolio targeting PACAP and combinatorial CGRP/PACAP pathways for preventive migraine therapy.
- Preventive therapy for inadequate CGRP responders
- Next-generation migraine biologics in clinic
- Subcutaneous dosing convenience for chronic migraine
Key facts
- Series A (Jun 2026): $46M from stealth
- Co-led by Westlake BioPartners and Canaan
- PACAP + CGRP combinatorial antibodies
- Human trials targeted ~2027 per MedPath
Funding history (newest first)
Investors in our directory
Funds linked from Vedana Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Deep migraine development bench — leaders from multiple approved migraine antibody programs per Business Wire.
Migraine biologics market is large but crowded; Vedana needs differentiated efficacy in CGRP non-responders and clean Phase 1/2 data.
-
Amgen/Novartis (Aimovig class CGRP) incumbent
Approved CGRP antibodies.
-
Biohaven/Pfizer migraine assets incumbent
Established acute and preventive brands.
-
Other PACAP biotech direct
Emerging same-pathway programs.
Notable stories
- BioSpace quoted Canaan's Julie Grant calling Vedana the 'deepest concentration of migraine expertise' the firm has seen.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Vedana Therapeutics's financing or category context.
FAQs about Vedana Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.